Stevanato Group (NYSE:STVN) Stock Crosses Below Two Hundred Day Moving Average Following Weak Earnings

Key Points

• Shares fell below their 200-day moving average after the earnings news, trading as low as €13.03 and last at €14.19, versus a 200-day average of €18.11.
• Third-quarter revenue increased 8% year over year to €326.1 million. Reported EPS of €0.16 narrowly missed analysts’ €0.17 estimate, although adjusted EPS was reported above consensus.
• Management expects only low-single-digit growth in 2027, citing lower GLP-1 syringe volumes from one customer, raising concerns about demand and customer concentration.

Stevanato Group S.p.A. (NYSE:STVN - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Tuesday following a dissappointing earnings announcement. The stock has a two hundred day moving average of €18.11 and traded as low as €13.03. Stevanato Group shares last traded at €14.19, with a volume of 4,785,200 shares.

The company reported €0.16 EPS for the quarter, missing analysts' consensus estimates of €0.17 by (€0.01). The company had revenue of €326.06 million during the quarter. Stevanato Group had a net margin of 10.99% and a return on equity of 10.43%.

Stevanato Group News Roundup

Here are the key news stories impacting Stevanato Group this week:

• Positive Sentiment: Third-quarter revenue rose 8% year over year to €326.1 million, and adjusted earnings of $0.18 per share topped the Zacks consensus estimate of $0.17. The results point to continued growth in the business despite concerns about future demand. Stevanato Group Q3 results
• Negative Sentiment: Management expects only low-single-digit growth in 2027, citing lower GLP-1 syringe volumes associated with one customer. The subdued forecast raised concerns about growth concentration and near-term demand, overshadowing the quarter’s revenue growth. 2027 outlook and GLP-1 syringe volumes
• Neutral Sentiment: A law firm announced an investigation into whether Stevanato’s investor disclosures complied with U.S. securities laws. The notice is an allegation of a pending review, not a finding of wrongdoing, but could add uncertainty for investors. Investigation notice

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. UBS Group started coverage on Stevanato Group in a report on Wednesday, September 9th. They set a "neutral" rating and a $23.00 price objective for the company. Deutsche Bank Aktiengesellschaft assumed coverage on Stevanato Group in a research note on Wednesday, October 7th. They issued a "hold" rating on the stock. Finally, Weiss Ratings raised Stevanato Group from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, August 27th. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy".

Insiders Place Their Bets

In related news, Director Elisabetta Magistretti sold 2,045 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of €20.09, for a total value of €41,084.05. Following the sale, the director owned 2,930 shares in the company, valued at approximately €58,863.70. This represents a 41.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Marco Dal Lago sold 4,209 shares of the firm's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of €20.09, for a total transaction of €84,558.81. Following the sale, the chief financial officer owned 81,144 shares of the company's stock, valued at approximately €1,630,182.96. This represents a 4.93% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 21,926 shares of company stock worth $459,738 over the last ninety days.

Hedge Funds Weigh In On Stevanato Group

A number of hedge funds have recently added to or reduced their stakes in STVN. Wellington Management Group LLP acquired a new position in shares of Stevanato Group in the second quarter worth approximately $22,621,000. Ranger Investment Management L.P. acquired a new stake in Stevanato Group during the 2nd quarter valued at approximately $21,438,000. Schwartz Investment Counsel Inc. increased its position in Stevanato Group by 15.0% during the 3rd quarter. Schwartz Investment Counsel Inc. now owns 661,136 shares of the company's stock valued at $13,871,000 after purchasing an additional 86,385 shares during the period. Fenimore Asset Management Inc acquired a new stake in Stevanato Group during the 3rd quarter valued at approximately $12,212,000. Finally, Cooper Investors PTY Ltd. raised its holdings in Stevanato Group by 4.4% during the 2nd quarter. Cooper Investors PTY Ltd. now owns 668,494 shares of the company's stock worth $12,080,000 after purchasing an additional 28,265 shares during the last quarter.

Stevanato Group Trading Down 28.1%

The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.08 and a current ratio of 1.61. The firm's fifty day simple moving average is €20.35 and its 200-day simple moving average is €18.11. The stock has a market cap of $4.30 billion, a P/E ratio of 25.34, a price-to-earnings-growth ratio of 1.62 and a beta of 0.80.

About Stevanato Group

Stevanato Group S.p.A. is an Italy-based provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and healthcare industries. Founded in 1949, the company has developed from a glass-packaging manufacturer into an integrated supplier serving customers throughout the global pharmaceutical supply chain.

The company manufactures primary packaging products, including glass vials, syringes, cartridges and ampoules, as well as components and systems used to contain and administer injectable medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.